

Analysis of SALVALAT product test data (2022-2023)

Tests were conducted in the following regions of Italy:

1. Malagnino (CR) – Province of Cremona, Lombardy Region

Application Date: October 25, 2023

Control Dates: October 2, 2022; December 2, 2022; January 2, 2023; February 2, 2023

No.	Cells	1st Control	2nd Control	3rd Control
84	1116	481	129	73
21	3566	20	875	321
309	677	83	55	71
30	1014	97	97	14

2. Revello (CN) – Province of Cuneo, Piedmont Region

Application Date: October 20, 2022

No.	Cells	1st Control	2nd Control
839	1909	150	160
751	1500	531	320
829	1377	86	90

3. Rodigo (MN) – Province of Mantua, Lombardy Region

Application Date: October 18, 2022

Control Dates: October 7, 2022; November 5, 2022; December 5, 2022; January 4, 2023

No.	Cells	1st Control	2nd Control	3rd Control
825	3156	822	1425	28
459	3659	31	155	53
662	2129	802	317	171
673	2900	224	230	dry period
730	3372	768	416	326
782	3154	786	623	97

4. Carpenedolo (BS) – Province of Brescia, Lombardy Region

Application Date: October 13, 2022

No.	Cells	1st Control	2nd Control	3rd Control
16	2015	236	138	84
148	4683	963	56	121

Trading Office: 68 Craven Park Road London N15 6AB

Web Site: www.clusternanotech.com

e-mail: info@clusternanotech.com

BANK HSBC IBAN GB20MIDL40051573566556 BIC MIDLGB22

VAT Number GB140901153 (EORI) Number – GB140901153000

Business relationships: [Kariné Musailova](mailto:Kariné.Musailova)

e-mail: export@clusternanotech.com

291	3500	743	dry period	-
329	5100	955	920	1114

5. Spineda (CR) – Province of Cremona, Lombardy Region

Application Date: November 15, 2022

No.	Cells	2nd Control
57	868	417
884	1200	50
892	1018	dry period
984	1905	103

Testing of SALVALAT Product on Dairy Farms in Italy

The testing of the SALVALAT product was conducted across various dairy farms in Italy to evaluate its effectiveness in reducing somatic cell count (SCC) levels in milk. High SCC levels in milk are a key indicator of subclinical or clinical mastitis in cows, negatively affecting milk quality and animal productivity.

Objective of the Study

To prevent mastitis, which often arises from bacterial infections.

To assess the antibacterial properties of SALVALAT and its ability to act as a barrier preventing pathogen penetration through the teat canal.

Testing Methodology

Cows diagnosed with subclinical mastitis were selected based on SCC analysis and the California Mastitis Test (CMT).

SALVALAT was introduced through a sterile catheter into the teat canal of each infected quarter of the udder. The product was administered slowly to ensure even distribution, reaching the udder cistern and milk ducts.

Control Measurements

Regular testing of SCC levels, as they correlate with udder inflammation and infection.

Observation of inflammation signs such as swelling, redness (hyperemia), and changes in milk consistency.

Measurements were conducted on predetermined dates post-application to evaluate both short-term and long-term effects.

Test Results

A significant decrease in SCC was observed in most animals throughout the testing period, confirming the anti-inflammatory properties of SALVALAT and its ability to limit bacterial growth.

Chronic mastitis cases or physiologically aging animals maintained high SCC levels, indicating the need for a more comprehensive approach to treatment and prevention.

Trading Office: 68 Craven Park Road London N15 6AB

Web Site: www.clusternanotech.com

e-mail: info@clusternanotech.com

BANK HSBC IBAN GB20MIDL40051573566556 BIC MIDLGB22

VAT Number GB140901153 (EORI) Number – GB140901153000

Business relationships: [Kariné Musailova](mailto:Kariné.Musailova)

e-mail: export@clusternanotech.com



Clusternanotech LTD
Nanostructured materials science
Office 4, 21 Knightsbridge - SW1X 7LY London UK
Company n.07961030
Capital Share: 9.080.193,00 € paid

*General Manager:
Bruno Cantarelli*

*Scientific Director:
Dr. Arturo Sommariva*

During the "dry period," some cows did not complete the full testing cycle due to lactation physiology.

Conclusion

SALVALAT demonstrates high efficacy as part of a mastitis prevention programme due to its antibacterial properties, which ensure a reduction in infection pressure. Barrier function, protecting the nipple canal from external pathogens. Chemical stability, preventing the active substances from entering the milk.

Recommendations

The product is recommended for use in udder health management programmes, especially during lactation, in conjunction with regular monitoring of somatic cell levels and hygiene measures.

Trading Office: 68 Craven Park Road London N15 6AB

Web Site: www.clusternanotech.com

e-mail: info@clusternanotech.com

BANK HSBC IBAN GB20MIDL40051573566556 BIC MIDLGB22

VAT Number GB140901153 (EORI) Number – GB140901153000

Business relationships: Kariné Musailova

e-mail: export@clusternanotech.com